key: cord-0990888-zjxjx6vb
authors: Nawa, N.; Kuramochi, J.; Sonoda, S.; Yamaoka, Y.; Nukui, Y.; Miyazaki, Y.; Fujiwara, T.
title: Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study
date: 2020-07-26
journal: nan
DOI: 10.1101/2020.07.20.20155945
sha: 6dbe565e85a32fccee31cbecda4db86adeb0ea65
doc_id: 990888
cord_uid: zjxjx6vb

Background: The number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan are substantially lower in comparison to the US and UK, potentially due to the under-implementation of polymerase chain reaction (PCR) tests. Studies reported that more than half of the SARS-CoV-2 infections are asymptomatic, confirming the importance for conducting seroepidemiological studies. Although the seroepidemiological studies in Japan observed a reported prevalence of 0.10% in Tokyo, 0.17% in Osaka, and 0.03% in Miyagi, sampling bias was not considered. The study objective was to assess the seroprevalence of SARS-CoV-2 in a random sample of households in Utsunomiya City in Tochigi Prefecture, Greater Tokyo, Japan. Methods: We launched the Utsunomiya COVID-19 seROprevalence Neighborhood Association (U-CORONA) Study to assess the seroprevalence of COVID-19 in Utsunomiya City. The survey was conducted between 14 June 2020 and 5 July 2020, in between the first and second wave of the pandemic. Invitations enclosed with a questionnaire were sent to 2,290 people in 1,000 households randomly selected from Utsunomiya basic resident registry. Written informed consent was obtained from all participants. The level of IgG antibodies to SARS-CoV-2 was assessed by chemiluminescence immunoassay analysis. Results: Among 2,290 candidates, 753 returned the questionnaire and 742 received IgG tests (32.4 % participation rate). Of the 742 participants, 86.8% were 18 years or older, 52.6% were women, 71.1% were residing within 10 km from the test clinic, and 89.2% were living with another person. The age and sex distribution, distance to clinic and police district were similar with those of non-participants, while the proportion of single-person households was higher among non-participants than participants (16.2% vs. 10.8%). We confirmed three positive cases through quantitative antibody testing. No positive cases were found among the people who live in the same household as someone with positive. All cases were afebrile. The estimated unweighted and weighted prevalence of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08-1.18%) and 1.23% (95% confidence interval: 0.17-2.28%), respectively. Conclusion: This study suggests the importance of detecting all cases using PCR or antigen testing, not only at a hospital, but also in areas where people assemble. Further prospective studies using this cohort are needed to monitor SARS-CoV-2 antibody levels.

The number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan are substantially lower in comparison to the US and UK, 1 potentially due to the under-implementation of polymerase chain reaction (PCR) tests. Studies reported that more than half of the SARS-CoV-2 infections are asymptomatic, 2 confirming the importance for conducting seroepidemiological studies. 3 Although the seroepidemiological studies in Japan observed a reported prevalence of 0.10% in Tokyo, 0.17% in Osaka, and 0.03% in Miyagi, 4 sampling bias was not considered. The study objective was to assess the seroprevalence of SARS-CoV-2 in a random sample of households in Utsunomiya City in Tochigi Prefecture, Greater Tokyo, Japan.

We launched the "Utsunomiya COVID-19 seROprevalence Neighborhood Association (U-CORONA)" Study to assess the seroprevalence of COVID-19 in Utsunomiya City. The survey was conducted between 14 June 2020 and 5 July 2020, in between the first and second wave of the pandemic (Figure 1 ). Invitations enclosed with a questionnaire were sent to 2,290 people in 1,000 households randomly selected from Utsunomiya City's basic resident registry. Written informed consent was obtained from all participants. The level of IgG antibodies to SARS-CoV-2 was assessed by chemiluminescence immunoassay analysis (Shenzhen YHLO Biotech Co., Ltd., Shenzhen, China). 5 According to the manufacturer, with a cut-off value of 10 AU/ml, the sensitivity and specificity of the assay was 97.3% and 96.3%, respectively. Using baseline data from the registry, age, sex, distance to clinic, residential district, and the number of cohabitants, multiple imputation was used to estimate the population-based prevalence. All analyses were conducted using STATA 14 (StataCorp LP, College Station, TX, USA) and R version 3.6.0 (R Core Team, 2019). This study was approved by the research ethics committee . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20155945 doi: medRxiv preprint at Tokyo Medical and Dental University.

Among 2,290 candidates, 753 returned the questionnaire and 742 received IgG tests (32.4 % participation rate). Of the 742 participants, 86.8% were 18 years or older, 52.6% were women, 71.1% were residing within 10 km from the test clinic, and 89.2% were living with another person. The age and sex distribution, distance to clinic and police district were similar with those of non-participants, while the proportion of single-person households was higher among non-participants than participants (16.2% vs. 10.8%).

We confirmed three positive cases through quantitative antibody testing. No positive cases were found among the people who live in the same household as someone with positive.

All cases were afebrile. The estimated unweighted and weighted prevalence of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08-1.18%) and 1.23% (95% confidence interval: 0.17-2.28%), respectively.

In this household and population-based seroprevalence study in Utsunomiya City, the unweighted and weighted seroprevalence of SARS-CoV-2 were 0.40% and 1.23%, respectively, much lower than Los Angeles in the US (4.31%), 6 suggesting that the majority of the population in Utsunomiya City was not infected. However, the number of unweighted and weighted estimated cases was 2,074 and 6,378 among 518,610 individuals, respectively, about 90 and 277 times higher than the number of confirmed cases in Utsunomiya City as of 14 June 2020, with 23 cases due to the first pandemic, respectively.

The study limitation is the low participation rate. Also, the study period was relatively long for seroprevalence study. Nonetheless, because we employed a household-based design, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. This study suggests the importance of detecting all cases using PCR or antigen testing, not only at a hospital, but also in areas where people assemble. Further prospective studies using this cohort are needed to monitor SARS-CoV-2 antibody levels.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20155945 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. .

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Technical Advisory Group for Infectious H. COVID-19: what is next for public health?

Updates on COVID-19 in Japan

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults